ReviewFrontiers in endocrinology2026
Glucolipid metabolic disorders and ferroptosis in diabetic ulcers: pathogenic crossroads and therapeutic opportunities.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has emerged as a key player in the pathogenesis of Diabetic Ulcers (DUs). Concurrently, Glucolipid Metabolic Disorders (GLMDs), driven by persistent hyperglycemia and lipotoxicity, constitute a core pathological basis for tissue damage and dysfunction of reparative cells. The interplay between ferroptosis and GLMDs represents a promising yet underexplored research area. This review synthesizes recent advances in understanding the molecular mechanisms underlying their interaction, focusing on how GLMDs drive ferroptosis by supplying lipid peroxidation substrates, inducing iron overload, and weakening antioxidant defenses. It also elaborates on how ferroptosis, in turn, exacerbates local metabolic stress and chronic inflammation through the release of Damage-Associated Molecular Patterns (DAMPs), thereby creating a vicious cycle. We propose that the ACSL4/Nrf2/AGEs-RAGE axis acts as a critical molecular hub integrating upstream metabolic insults with downstream ferroptotic execution, representing a novel and targetable pathogenic circuit in DUs. Modulating key molecules within this axis (e.g., ACSL4, GPX4, Nrf2) offers promising therapeutic strategies for breaking this cycle, either by selectively eliminating harmful cells or protecting reparative ones. This review aims to bridge current knowledge gaps and provide a mechanistic foundation for developing innovative therapies that combine metabolic regulation with ferroptosis intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.